Open AccessNevirapine induced Stevens-Johnson syndrome in an HIV infected patient
Author(s) -
Harminder Singh,
Vinay Kumar Kachhap,
Bithika Nel Kumar,
Kalpayak
Publication year - 2011
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.75680
Subject(s) - nevirapine , medicine , tolerability , regimen , adverse effect , reverse transcriptase inhibitor , nucleoside analogue , virology , nucleoside reverse transcriptase inhibitor , human immunodeficiency virus (hiv) , pharmacology , immunology , dermatology , antiretroviral therapy , viral load , nucleoside , biology , biochemistry
Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is widely prescribed as a part of the combination therapy of human immunodeficiency virus (HIV) infection because of its efficacy and good tolerability. Here, we report a case of Stevens-Johnson syndrome (SJS) secondary to nevirapine. The patient had a diffuse, exfoliating exanthema with generalized bullous eruptions that involved the face, trunk and both extremities with elevated hepatic alanine aminotransferase and aspartate aminotransferase enzyme activities. The condition improved with stoppage of nevirapine-based highly active antiretroviral therapy (HAART) regimen, so we attributed this adverse event to nevirapine. A strict vigilance of adverse drug reaction is required in HAART.